Individual-specific changes in the human gut microbiota after challenge with enterotoxigenic Escherichia coli and subsequent ciprofloxacin treatment

BMC Genomics

Volumn 17, Issue 1, 2016, Pages

  Pop, Mihai ^a,b   Paulson, Joseph N ^a,c,d,e   Chakraborty, Subhra ^f   Astrovskaya, Irina ^a   Lindsay, Brianna R ^g,h   Li, Shan ^g   Bravo, Héctor Corrada ^a,b   Harro, Clayton ^f   Parkhill, Julian ⁱ   Walker, Alan W ^i,j   Walker, Richard I ^k   Sack, David A ^f   Stine, O Colin ^g  

^a University of Maryland   (United States)

^b Institute of Advanced Computer Science   (United States)

^c UNIVERSITY OF MARYLAND   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

^e HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^f JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^g UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^h MERCK RESEARCH LABORATORIES   (United States)

ⁱ WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^j ROWETT RESEARCH INSTITUTE   (United Kingdom)

^k PATH   (United States)

more..

Author keywords

16S rRNA gene survey; Antibiotic treatment; Diarrhea; Enterotoxigenic escherichia coli; Microbiota

Indexed keywords

CIPROFLOXACIN; RNA 16S;

ADULT; ARTICLE; BACTERIAL SHEDDING; CONTROLLED STUDY; DIARRHEA; ENTEROTOXIGENIC ESCHERICHIA COLI; FECES CULTURE; FECES MICROFLORA; FEMALE; FOLLOW UP; GENE SEQUENCE; HUMAN; HUMAN EXPERIMENT; INTESTINE FLORA; MALE; MICROBIAL DIVERSITY; NORMAL HUMAN; POLYMERASE CHAIN REACTION; DRUG EFFECTS; ESCHERICHIA COLI INFECTIONS; FECES; HIGH THROUGHPUT SEQUENCING; METAGENOME; METAGENOMICS; MICROBIOLOGY; MIDDLE AGED; PHYSIOLOGY; PROCEDURES; RECEIVER OPERATING CHARACTERISTIC; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; CIPROFLOXACIN; DIARRHEA; ENTEROTOXIGENIC ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FECES; FEMALE; GASTROINTESTINAL MICROBIOME; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MALE; METAGENOME; METAGENOMICS; MIDDLE AGED; RNA, RIBOSOMAL, 16S; ROC CURVE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84975761163     PISSN: None     EISSN: 14712164     Source Type: Journal    
DOI: 10.1186/s12864-016-2777-0     Document Type: Article

References (47)

1. Qadri F, Svennerholm AM, Faruque AS, Sack RB. Enterotoxigenic Escherichia coli in developing countries: epidemiology, microbiology, clinical features, treatment, and prevention. Clin Microbiol Rev. 2005;18(3):465-83.
2. Bourgeois AL, Wierzba TF, Walker RI. Status of vaccine research and development for enterotoxigenic Escherichia coli. Vaccine. 2016;34(26):2880-6.
3. Havelaar AH, Kirk MD, Torgerson PR, Gibb HJ, Hald T, Lake RJ, Praet N, Bellinger DC, de Silva NR, Gargouri N et al. World Health Organization Global estimates and regional comparisons of the burden of foodborne disease in 2010. PLoS Med. 2015;12(12):e1001923.
4. Svennerholm AM, Lundgren A. Recent progress toward an enterotoxigenic Escherichia coli vaccine. Expert Rev Vaccines. 2012;11(4):495-507.
5. Harro C, Chakraborty S, Feller A, DeNearing B, Cage A, Ram M, Lundgren A, Svennerholm AM, Bourgeois AL, Walker RI, et al. Refinement of a human challenge model for evaluation of enterotoxigenic Escherichia coli vaccines. Clin Vaccine Immunol. 2011;18(10):1719-27.
6. Gill SR, Pop M, Deboy RT, Eckburg PB, Turnbaugh PJ, Samuel BS, Gordon JI, Relman DA, Fraser-Liggett CM, Nelson KE. Metagenomic analysis of the human distal gut microbiome. Science. 2006;312(5778):1355-9.
7. Backhed F, Ley RE, Sonnenburg JL, Peterson DA, Gordon JI. Host-bacterial mutualism in the human intestine. Science. 2005;307(5717):1915-20.
8. Li M, Wang B, Zhang M, Rantalainen M, Wang S, Zhou H, Zhang Y, Shen J, Pang X, Zhang M, et al. Symbiotic gut microbes modulate human metabolic phenotypes. Proc Natl Acad Sci U S A. 2008;105(6):2117-22.
9. Hooper LV. Bacterial contributions to mammalian gut development. Trends Microbiol. 2004;12(3):129-34.
10. Mazmanian SK, Liu CH, Tzianabos AO, Kasper DL. An immunomodulatory molecule of symbiotic bacteria directs maturation of the host immune system. Cell. 2005;122(1):107-18.
11. Maynard CL, Elson CO, Hatton RD, Weaver CT. Reciprocal interactions of the intestinal microbiota and immune system. Nature. 2012;489(7415):231-41.
12. Round JL, Mazmanian SK. The gut microbiota shapes intestinal immune responses during health and disease. Nat Rev Immunol. 2009;9(5):313-23.
13. Stecher B, Hardt WD. Mechanisms controlling pathogen colonization of the gut. Curr Opin Microbiol. 2011;14(1):82-91.
14. Keeney KM, Finlay BB. Enteric pathogen exploitation of the microbiota-generated nutrient environment of the gut. Curr Opin Microbiol. 2011;14(1):92-8.
15. Servin AL. Antagonistic activities of lactobacilli and bifidobacteria against microbial pathogens. FEMS Microbiol Rev. 2004;28(4):405-40.
16. Walker AW, Ince J, Duncan SH, Webster LM, Holtrop G, Ze X, Brown D, Stares MD, Scott P, Bergerat A, et al. Dominant and diet-responsive groups of bacteria within the human colonic microbiota. ISME J. 2011;5(2):220-30.
17. Wu GD, Chen J, Hoffmann C, Bittinger K, Chen YY, Keilbaugh SA, Bewtra M, Knights D, Walters WA, Knight R, et al. Linking long-term dietary patterns with gut microbial enterotypes. Science. 2011;334(6052):105-8.
18. Koren O, Goodrich JK, Cullender TC, Spor A, Laitinen K, Backhed HK, Gonzalez A, Werner JJ, Angenent LT, Knight R, et al. Host remodeling of the gut microbiome and metabolic changes during pregnancy. Cell. 2012;150(3):470-80.
19. Claesson MJ, Cusack S, O'Sullivan O, Greene-Diniz R, de Weerd H, Flannery E, Marchesi JR, Falush D, Dinan T, Fitzgerald G, et al. Composition, variability, and temporal stability of the intestinal microbiota of the elderly. Proc Natl Acad Sci U S A. 2011;108 Suppl 1:4586-91.
20. Pop M, Walker AW, Paulson J, Lindsay B, Antonio M, Hossain M, Oundo J, Tamboura B, Mai V, Astrovskaya I, et al. Diarrhea in young children from low-income countries leads to large-scale alterations in intestinal microbiota composition. Genome Biol. 2014;15(6):R76.
21. Dethlefsen L, Huse S, Sogin ML, Relman DA. The pervasive effects of an antibiotic on the human gut microbiota, as revealed by deep 16S rRNA sequencing. PLoS Biol. 2008;6(11):e280.
22. Rashid MU, Zaura E, Buijs MJ, Keijser BJ, Crielaard W, Nord CE, Weintraub A. Determining the long-term effect of antibiotic administration on the human normal intestinal microbiota using culture and pyrosequencing methods. Clin Infect Dis. 2015;60 Suppl 2:S77-84.
23. Nyberg SD, Osterblad M, Hakanen AJ, Lofmark S, Edlund C, Huovinen P, Jalava J. Long-term antimicrobial resistance in Escherichia coli from human intestinal microbiota after administration of clindamycin. Scand J Infect Dis. 2007;39(6-7):514-20.
24. Dethlefsen L, Relman DA. Incomplete recovery and individualized responses of the human distal gut microbiota to repeated antibiotic perturbation. Proc Natl Acad Sci U S A. 2011;108 Suppl 1:4554-61.
25. Warren CA, Guerrant RL. Pathogenic C difficile is here (and everywhere) to stay. Lancet. 2011;377(9759):8-9.
26. Jernberg C, Lofmark S, Edlund C, Jansson JK. Long-term ecological impacts of antibiotic administration on the human intestinal microbiota. ISME J. 2007;1(1):56-66.
27. Jernberg C, Lofmark S, Edlund C, Jansson JK. Long-term impacts of antibiotic exposure on the human intestinal microbiota. Microbiol. 2010;156(Pt 11):3216-23.
28. Jakobsson HE, Jernberg C, Andersson AF, Sjolund-Karlsson M, Jansson JK, Engstrand L. Short-term antibiotic treatment has differing long-term impacts on the human throat and gut microbiome. PLoS One. 2010;5(3):e9836.
29. Beaugerie L, Petit JC. Microbial-gut interactions in health and disease. Antibiotic-associated diarrhoea. Best Pract Res Clin Gastroenterol. 2004;18(2):337-52.
30. Macfarlane S, Steed H, Macfarlane GT. Intestinal bacteria and inflammatory bowel disease. Crit Rev Clin Lab Sci. 2009;46(1):25-54.
31. Kassinen A, Krogius-Kurikka L, Makivuokko H, Rinttila T, Paulin L, Corander J, Malinen E, Apajalahti J, Palva A. The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects. Gastroenterol. 2007;133(1):24-33.
32. Wilcox MH. Gastrointestinal disorders and the critically ill. Clostridium difficile infection and pseudomembranous colitis. Best Pract Res Clin Gastroenterol. 2003;17(3):475-93.
33. O'Keefe SJ, Chung D, Mahmoud N, Sepulveda AR, Manafe M, Arch J, Adada H, van der Merwe T. Why do African Americans get more colon cancer than Native Africans? J Nutr. 2007;137(1 Suppl):175S-82.
34. McGarr SE, Ridlon JM, Hylemon PB. Diet, anaerobic bacterial metabolism, and colon cancer: a review of the literature. J Clin Gastroenterol. 2005;39(2):98-109.
35. Candela M, Turroni S, Biagi E, Carbonero F, Rampelli S, Fiorentini C, Brigidi P. Inflammation and colorectal cancer, when microbiota-host mutualism breaks. World J Gastroenterol. 2014;20(4):908-22.
36. Lindsay BR, Chakraborty S, Harro C, Li S, Nataro JP, Sommerfelt H, Sack DA, Colin Stine O. Quantitative PCR and culture evaluation for enterotoxigenic Escherichia coli (ETEC) associated diarrhea in volunteers. FEMS Microbiol Lett. 2014;352(1):25-31.
37. Ghodsi M, Liu B, Pop M. DNACLUST: accurate and efficient clustering of phylogenetic marker genes. BMC Bioinformatics. 2011;12:271.
38. Cole JR, Chai B, Farris RJ, Wang Q, Kulam SA, McGarrell DM, Garrity GM, Tiedje JM. The Ribosomal Database Project (RDP-II): sequences and tools for high-throughput rRNA analysis. Nucleic Acids Res. 2005;33(Database issue):D294-6.
39. Edgar RC, Haas BJ, Clemente JC, Quince C, Knight R. UCHIME improves sensitivity and speed of chimera detection. Bioinformatics. 2011;27(16):2194-200.
40. Paulson JN, Stine OC, Bravo HC, Pop M. Differential abundance analysis for microbial marker-gene surveys. Nat Methods. 2013;10(12):1200-2.
41. Bates D, Mächler M, Bolker B, Walker S. Fitting linear mixed-effects models using lme4. 2014. arXiv preprint arXiv:14065823.
42. Jari O, Blanchet FG, Roeland K, Pierre L, Peter RM, Hara RBO, Gavin LS, Peter S, Stevens MHH, Helene W. vegan: Community Ecology Package. 2015
43. Lindsay B, Oundo J, Hossain MA, Antonio M, Tamboura B, Walker AW, Paulson JN, Parkhill J, Omore R, Faruque AS et al. Microbiota that affect risk for shigellosis in children in low-income countries. Emerg Infect Dis. 2015;21(2):242-50.
44. Lawley TD, Clare S, Walker AW, Stares MD, Connor TR, Raisen C, Goulding D, Rad R, Schreiber F, Brandt C, et al. Targeted restoration of the intestinal microbiota with a simple, defined bacteriotherapy resolves relapsing Clostridium difficile disease in mice. PLoS Pathog. 2012;8(10):e1002995.
45. Ubeda C, Bucci V, Caballero S, Djukovic A, Toussaint NC, Equinda M, Lipuma L, Ling L, Gobourne A, No D, et al. Intestinal microbiota containing Barnesiella species cures vancomycin-resistant Enterococcus faecium colonization. Infect Immun. 2013;81(3):965-73.
46. Buffie CG, Bucci V, Stein RR, McKenney PT, Ling L, Gobourne A, No D, Liu H, Kinnebrew M, Viale A, et al. Precision microbiome reconstitution restores bile acid mediated resistance to Clostridium difficile. Nature. 2015;517(7533):205-8.
47. Wick EC, Sears CL. Bacteroides spp. and diarrhea. Curr Opin Infect Dis. 2010;23(5):470-4.